Jaguar Animal Health Completes Enrollment for Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
Top-line results from this prospective, masked, randomized, negative
controlled study are expected to be available this coming February.
Strict enrollment criteria required patients to have both squamous and
glandular gastric ulcerations. As Jaguar stated on
"Until recently, treatment recommendations for equine ulcers have not
differentiated between squamous and glandular disease. However, a series
of recent third-party studies indicate considerably lower healing rates
for glandular ulcers with standard of care (e.g. omeprazole).3
Subclinically, these lesions can compromise athletic performance,”
According to a third-party 2005 study, as many as 55% of performance
horses have colonic or gastric ulcers and 97% of performance horses have
either a gastric (87%) or a colonic (63%) ulcer.4 Data from
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the availability, before February, of results from Jaguar’s proof-of-concept study to evaluate the safety and effectiveness of SB-300 for the treatment of gastrointestinal ulcers in horses, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1Habershon-Butcher, J.L., Hallowell, G.D., Bowen, I.M.,
Sykes, B. (2012), Prevalence and risk factors for ulceration of the
gastric glandular mucosa in thoroughbred race horses in training in the
2Vatistas, N.J., Synder, J.R.,
3Sykes, B.W., Hewetson, M., Hepburn, R.J., Luthersson, N. and Tamzali, Y. (2015),
4Pellegrini, F.L. (2005), Results of a large-scale necroscopic study of equine colonic ulcers. J Equine Vet Sci; 25 (3): pp. 113-117.